Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 26, 844–845 (1 August 2008) | doi:10.1038/nbt0808-844
Infections cast cloud over Novartis' MS therapy
Abstract
Novartis' small molecule FTY720 (fingolimod), now in phase 3, is a potential threat to Biogen Idec's lucrative multiple sclerosis (MS) franchise. But in June Novartis reported that two phase 3 patients had suffered devastating viral infections, one fatal.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
